Influence of Liposomes and Niosomes on the In Vitro Permeation and Skin Retention of Finasteride Permeation study of finasteride-entrapped vesicles
Iranian Journal of Pharmaceutical Sciences,
卷 1 编号 3 (2005),
1 تیر 2005
,
第 119-130 页
https://doi.org/10.22037/ijps.v1.39486
摘要
In this work we sought to determine whether vesicles (liposomes/niosomes) were able to enhance finasteride concentration in the dermis layer, including the pilosebaceous units (PSU). Such enhancement could be beneficial in the treatment of some androgen-related skin disorders. Hamster flank skin was used to study 3Hfinasteride permeation via vesicles and a hydroalcoholic solution (HA). The drug-containing vesicles were composed of dimyristoyl phosphatidylcholine (DMPC) or egg lecithin: cholesterol: dicetyl phosphate (liposomes) and polyoxyethylene alkyl ethers (Brij® series) or sorbitan monopalmitate (Span 40):
cholesterol: dicetyl phosphate (niosomes) and were prepared by the film hydration technique. Determination of finasteride content by HPLC showed 80-97% drug entrapment efficiency in the vesicles. The amount of 3H-finasteride penetrated into and permeated through hamster skin 24 h after topical application of vesicles ranged from 5.5 to 13% of the initial dose, compared to 24%, observed with HA (p<0.05). The amount of finasteride deposited within the different skin strata via gelstate Span 40 and lecithin vesicles was lower, when compared with liquid-state Brij97, Brij 76: Brij 97 and DMPC vesicles. The fraction of finasteride found in the dermis layer was greatest where DMPC liposomes were used (7.8%). The vesicles significantly reduced drug permeation as indicated by the flux of finasteride from vesicles (0.025-0.058 µg/cm2.h), where compared with the HA (0.13 µg/cm2.h), (p<0.01). This study demonstrated the potentials of liquid-state vesicles in reducing the percutaneous absorption of finasteride and increasing its concentration and retention in the dermis layer.
- Deposition
- DSC
- Finasteride
- Liposome
- Niosome
- Permeation
##submission.howToCite##
参考
[2] Chen C, Puy LA, Simard J, Li X, Singh SM, Labrie F. Local and systemic reduction by topical finasteride or flutamide of hamster flank organ size and enzyme activity. J Invest Dermatol 1995; 105: 678-82.
[3] Matias JR, Orentreich N. The hamster ear sebaceous glands. I. Examination of the regional variation by stripped skin planimetry. J Invest Dermatol 1983; 81: 43-6.
[4] Matias JR, Malloy VL, Orentreich N. Synergistic antiandrogenic effects of topical combinations of 5 alpha-reductase and androgen receptor inhibitors in the hamster sebaceous glands. J Invest Dermatol 1988; 91: 429-33.
[5] Bull HG, Miller RR, Stearns RA, Bakshi RK, Rasmusson GH. Mechanism-based inhibition of human steroid 5 a-reductase by finasteride: enzyme catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor. J Am Chem Soc 1996; 118: 2359-65.
[6] Tian G, Stuart JD, Moss ML, Domanico PL, Bramson HN, Patel IR, Kawdell SH, Overton LK, Kost TA, Mook RA, Frye SV, Batchelor KW, Wiseman JS. 17b-(n-tert-butylcarbamoyl)- 4-aza-5a-androstan-1-ene-3-one is an active site-directed slow time-dependent inhibitor of human steroid 5a-reductase 1. Biochemistry 1994; 33: 2291-6.
[7] Chen W, Zouboulis CC, Orfanos CE. The 5areductase system and its inhibitors: recent development and its perspective in treating androgen-dependent skin disorders. Dermatology 1996; 193: 177-84.
[8] Archer JS, Chang RJ. Hirsutism and acne in polycystic ovary syndrome. Best Pract Res Clin Obstet Gynecol 2004; 18: 737-54.
[9] Moghetti P, Castello R, Magnani CM, Tosi F, Negri C, Armanini D, Bellotti G, Muggeo M. Clinical and hormonal effects of the 5 alphareductase inhibitor finasteride in idiopathic hirsutism. J Clin Endocrinol Metab 1994; 79: 1115-21.
[10] Wong IL, Morris RS, Chang L, Spahn MA, Stanczyl FZ, Lobo RA. Aprospective randomized trial comparing finasteride to spironolactone in the treatment of hirsute women. J Clin Endocrinol Metab 1995; 80: 233-8.
[11] Meidan VM, Touitou E. Treatment for androgenetic alopecia and alopecia areata. Drugs 2001; 61: 53-69.
[12] Dallob AL, Sadick NS, Unger W, Lipert S, Geissler LA, Gregoire SL, Nguyen HH, Moore EC, Tanaka WK. The effect of finasteride, a 5areductase inhibitor, on scalp skin testosterone and dihydrotestosterone concentrations in patients with male pattern baldness. J Clin Endocrinol Metab 1994; 79: 703-6.
[13] Drake L, Hordinsky M, Fiedler V, Swinehart J, Unger WP, Cotterill PC, Thiboutot DM, Lowe N. The effect of finasteride on scalp skin and serum androgen level in men with androgenetic alopecia. J Am Acad Dermatol 1999; 41: 550-4.
[14] Shapiro J, Kaufman KD. Use of finasteride in the treatment of men with androgenetic alopecia (male pattern hair loss). J Investig Dermatol Symp Proc 2003; 8: 20-3.
[15] Kaufman KD, Olsen EA, Whitimg D. Finasteride in the treatment of men with androgenetic alopecia. J Am Acad Dermatol 1998; 39: 578-89.
[16] Mazzarella F, Loconsole F, Cammisa A, Mastrolonardo M, Vena G. Topical finasteride in the treatment of androgenic alopecia. Preliminary evaluations after a 16-month therapy course. J Dermatol Treat 1997; 8: 189-92.
[17] Lieb LM, Ramachandran C, Egbaria K, Weiner N. Topical delivery enhancement with multilamellar liposomes into pilosebaceous units: I. In vitro evaluation using fluorescent techniques with the hamster ear model. J Invest Dermatol 1992; 99: 108-13.
[18] Wu HL, Ramachandran C, Weiner N, Roessler BJ. Topical transport of hydrophilic compounds using water-in-oil nanoemulsions. Int J Pharm 2001; 220: 63-75.
[19] Lieb LM, Liimatta AP, Bryan RN, Krueger GG. Description and definition of a transfollicular route of permeant for topically applied agents to human scalp skin. J Invest Dermatol 1995; 104: 655.
[20] Rolland A, Wagner N, Chatelus A, Shroot B, Schaefer H. Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm Res 1993; 10: 1738-44.
[21] Sumian CC, Pitre FB, Gauthier BE, Bouclier M, Mordon SR. A new method to improve penetration depth of dyes into the follicular duct: potential application for laser hair removal. J Am Acad Derm 1999; 41: 172-5.
[22] Green PG, Hinz RS, Kim A, Szoka FC, Guy RH. Iontophoretic delivery of a series of tripeptides across the skin in vitro. Pharm Res 1991; 8: 1121-7.
[23] Cullander C, Guy RH. Sites of iontophoretic current flow into the skin: identification and characterization with the vibrating probe electrode. J Invest Dermatol 1991; 97: 55-64.
[24] Burnette RR, Ongpipattanakul B. Characterization of the pore transport properties and tissue alteration of excised human skin during iontophoresis. J Pharm Sci 1988; 77: 132-7.
[25] Lauer AC, Lieb LM, Ramachandran C, Flynn GL, Weiner N. Transfollicular drug delivery. Pharm Res 1995; 12: 179-86.
[26] Lauer AC, Ramachandran C, Lieb LM, Niemiec SM, Weiner N. Targeted delivery to the pilosebaceous unit via liposomes. Adv Drug Deliv Rev 1996; 18: 311-24.
[27] Li L, Lishko VK, Margolis LB, Hoffman RM. Product-delivering liposomes specifically target hair follicles in histocultured intact skin. In Vitro Cell Dev Biol 1992; 28A: 679-81.
[28] Bernard E, Dubios J, Wepierre J. Importance of sebaceous glands in cutaneous penetration of an antiandrogen: target effect of liposomes. J Pharm Sci 1997; 86: 573-8.
[29] Niemiec SM, Ramachandran C, Weiner N. Influence of nonionic liposomal composition on topical delivery of peptide drug into pilosebaceous units: an in vivo study using the hamster ear model. Pharm Res 1995; 12: 1184-8.
[30] Weiner N. Targeted follicular delivery of macromolecular via liposomes. Int J Pharm 1998; 162: 29-38.
[31] Balsari AL, Morelli D, Menard S, Veronesi U, Colnaghi MI. Protection against doxorubicininduced alopecia in rats by liposome-entrapped monoclonal antibodies. FASEB J 1994; 8: 226-30.
[32] Li L, Lishko V, Hoffman RM. Liposome targeting of high molecular weight DNA to the hair follicles of histocultured skin: a model for gene therapy of the hair growth processes. In Vitro Cell Dev Biol 1993; 29A: 258-60.
[33] Li L, Lishko V, Hoffman RM. Liposomes can specifically target entrapped melanin to hair follicles in histocultured skin. In Vitro Cell Dev Biol 1993; 29A: 192-4.
[34] Bouwstra JA, van Hal DA, Hofland HEJ, Junginger HE. Preparation and characterization of nonionic surfactant vesicles. Colloids Surf A: Physicochem Eng Aspects 1997; 123-4: 71-80.
[35] Lawrence MJ, Chauhan S, Lawrence SM, Barlow DJ. The formation, characterization and stability of non-ionic surfactant vesicles. S T P Pharma Sciences 1996; 6: 49-60.
[36] Manosroi A, Wongtrakul P, Manosroi J, Sakai H, Sugawara F, Yuasa M, Abe M. Characterization of vesicles prepared with various non-ionic surfactants mixed with cholesterol. Coll Surf B Biointerf 2003; 30: 129-38.
[37] Varshosaz J, Pardakhty A, Hajhashemi V, Najafabadi AR. Development and physical characterization of sorbitan monoester niosomes for insulin oral delivery. Drug Deliv 2003; 10: 251-62.
[38] Bernard E, Dubios JL, Wepierre J. Percutaneous absorption of a new antiandrogen included in liposomes or in solution. Int J Pharm 1995; 126: 235-43.
[39] Han I, Kim M, Kim J. Enhanced transfollicular delivery of adriamycin with a liposome and iontophoresis. Exp Dermatol 2004; 13: 86-92.
[40] Ogiso T, Shiraki T, Okajima K, Tanino T, Iwaki M, Wada T. Transfollicular drug delivery: penetration of drugs through human scalp skin and comparison of penetration between scalp and abdominal skins in vitro. J Drug Target 2002; 10: 369-78.
[41] Touitou E, Levi-Schaffer F, Dayan N, Alhaique F, Riccierr F. Modulation of caffeine skin delivery by carrier design: liposomes versus permeation enhancers. Int J Pharm 1994; 103: 131-6.
[42] Touitou E, Junginger HE, Weiner N, Nagai T, Mezei M. Liposomes as carriers for topical and transdermal delivery. J Pharm Sci 1994; 83: 1189- 203.
[43] Uchegbu IF, Vyas SP. Non-ionic surfactant based vesicles (niosomes) in drug delivery. Int J Pharm 1998; 172: 70.
[44] Baillie AJ, Florence AT, Hume LR, Muirhead GT, Rogerson A. The preparation and properties of niosomes-nonionic surfactant vesicles. J Pharm Pharmacol 1985; 37: 863-8.
[45] Bonina F, Montenegro L. Comparison of different separative techniques in the quantitative determination of active compound enclosed in liposomal systems. Int J Cosmet Sci 1994; 16: 183-97.
[46] Fildes FJT, Oliver JE. Interaction of cortisol-21- palmitate with liposomes examined by differential scanning calorimetry. J Pharm Pharmacol 1978; 30: 337-42.
[47] Ford JL, Timmins P. The use of thermal analysis in the study of liposomes. In: Ford JL, Timmins P, (editors). Pharmaceutical thermal analysis. Chichester: Elis Horwood Limited; 1989; pp. 259-78.
[48] Montenegro L, Panico AM, Bonina F. Quantitative determination of hydrophobic compound entrapped in dipalmitoylphosphatidylcholine liposomes by differential scanning calorimetry. Int J Pharm 1996; 138: 191-7.
[49] Roberts MS, Cross SE. Skin transport. In: Walters KA, (editor). Dermatological and transdermal formulations. New York: Marcel Dekker, Inc., 2002; pp. 89-196.
[50] Ganesan MG, Weiner ND, Flynn GL, Ho NFH. Influence of liposomal drug entrapment on percutaneous absorption. Int J Pharm 1984; 20: 139-54.
[51] Sarpotdar PP, Zatz JL. Percutaneous absorption enhancement by nonionic surfactants. Drug Dev Ind Pharm 1986;12:1625-47.
[52] Hofland HEJ, Geest R, Bodde HE, Junginger HE, Bouwstra JA. Estradiol permeation from nonionic surfactant vesicles through human stratum corneum in vitro. Pharm Res 1994; 11: 659-64.
[53] Fang JY, Hong CT, Chiu WT, Wang YY. Effect of liposomes and niosomes on skin permeation of enoxacin. Int J Pharm 2001; 219: 61-72.
[54] Valjakka-Koskela R, Kirjavainen M, Monkkonen J. Enhancement of percutaneous absorption of naproxen by phospholipids. Int J Pharm 1998; 175: 225-30.
[55] Weiner N, Martin F, Riaz M. Liposomes as a drug delivery system. Drug Dev Ind Pharm 1989; 15: 1523-54.129.
- 摘要 ##plugins.themes.ojsPlusA.frontend.article.viewed##: 90 ##plugins.themes.ojsPlusA.frontend.article.times##
- IJPS_Volume 1_Issue 3_Pages 119-130 (English) ##plugins.themes.ojsPlusA.frontend.article.downloaded##: 46 ##plugins.themes.ojsPlusA.frontend.article.times##